Published in Hepatitis Weekly, May 17th, 2004
The study, "Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs," suggests Hemispherx' s lead drug, Alferon N Injection, tested among 19 clinically approved compounds from several major antiviral pharmacologic classes, exhibits the most potent antiviral activity in an in-vitro model of SARS-CoV infection and is a potential drug for in-vivo research. Companies contributing approved products included Roche, Schering-Plough, GlaxoSmithKline, Serono, Merck, Schering, AG, Novartis,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly